Roth Capital Keeps BioLineRx (BLRX) at 'Buy' Amid New in-Licensing Agreement
Tweet Send to a Friend
Roth Capital affirms BioLineRx Ltd. (Nasdaq: BLRX) with a Buy rating and $7 price target after the company announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
